William J. Kullback

Chief Financial Officer

William J. Kullback.  Mr. Kullback has served as our Chief Financial Officer since August 2023.  As CFO, Mr. Kullback has responsibility for the Company’s financial planning and analysis, accounting, internal audit, tax, and treasury functions. He has more than twenty-eight years of experience as a Chief Financial Officer in a broad range of financial management and operational roles, primarily in mid-sized to large corporations, including multiple publicly held life-science companies.  Prior to joining Telesis Bio, Mr. Kullback served for five plus years as CFO of BioLegend, Inc., a worldwide provider of life science antibodies and reagents, where he led the company’s September 2021 sale to NYSE listed Revvity (formerly PerkinElmer) for $5.25 billion, the largest acquisition in PerkinElmer’s history.   Before joining BioLegend in 2017, Mr. Kullback served as Chief Financial Officer of Lombard Medical, Inc. (Nasdaq: EVAR), a medical device company, from 2014 to 2017, prior to its acquisition by MicroPort Scientific Corporation, a Shanghai, China based medical device group. Similar CFO appointments at other medical device and technology companies have resulted in a host of successful transactions involving debt, M&A buy-side, M&A sell-side, and public offerings. Mr. Kullback earned both his MBA and bachelor’s degree from the State University of New York at Buffalo.